Pharmaceutical Technology11d
COPD market to expand with AstraZeneca’s focus on biologics and strong portfolio growth
The upcoming release of Phase III Fasenra data in COPD in 2025 is expected to solidify AstraZeneca’s position in the market.
Healio1d
Metered-dose to dry-powder inhaler switch not often reversed in veterans
A small proportion of veterans who went from a metered-dose inhaler to a dry-powder inhaler had to revert to the metered-dose ...
The Financial Express9d
AstraZeneca’s Fasenra set to revolutionise COPD treatment as Phase III data builds anticipation
AstraZeneca’s respiratory and immunology portfolio is driving significant growth, with R&I assets forecasted to account for ...
The Pharma Letter11d
AstraZeneca's Fasenra set to revolutionize COPD treatment
UK pharma major AstraZeneca’s Fasenra (benralizumab), with its highly anticipated Phase III data to be showcased at the 2025 ...
pulmonologyadvisor6d
In COPD Treatment, Tezepelumab Not Linked to Reduced Exacerbations
Tezepelumab did not significantly decrease moderate or severe COPD exacerbations compared with placebo, the COURSE trial found.
pharmaphorum3d
‘Real world’ COPD trial gives GSK a dose of reality
GlaxoSmithKline (GSK) has announced full results from the Salford Lung Study (SLS), a pioneering study of COPD treatment aimed ... the likes of Novartis and AstraZeneca. Novartis yesterday ...
Yahoo Finance11d
COPD market to expand with AstraZeneca’s focus on biologics and strong portfolio growth
Dupixent’s success has highlighted the potential of biologics to target specific inflammatory pathways in COPD, a space previously dominated by inhaled therapies. AstraZeneca’s Fasenra ...
pharmaphorum2d
AstraZeneca, Honeywell partner to address climate change with new inhaler tech
Starting with the Brestri Aerosphere COPD inhaler (pending regulatory approval), AstraZeneca intends to transition all of its MDIs to this technology by 2030. “The work we are doing with ...